Hepatocellular Carcinoma
Conditions
Brief summary
This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC. Multiple logistic regression analysis will be performed to evaluate the association between statin therapy and the risk of HCC recurrence after LT.
Interventions
DRUGStatin
Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
Sponsors
Yonsei University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who received LT at the Severance Hospital from 2006 to 2016.
Exclusion criteria
* early postoperative mortality (defined as death within 2 months after LT without signs of tumor recurrence) * patient with distant lymph node metastasis confirmed within 1 month after LT * Patients younger than 20 years of age * patients who had LT for cirrhosis without confirmed HCC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC. | up to December, 2017 | Usually, liver CT is performed at 1 week, 1 month, 6 months, and every year until 5 years after surgery. Afterwards, liver CT is performed at 2-year intervals. Measurement of blood tumor markers \[AFP and prothrombin induced by vitamin K absence-II\] is performed every month for 6 months after discharge from the hospital and every 3 months thereafter. Additional liver CT, liver magnetic resonance imaging, or positron emission tomography-CT is performed when elevated tumor markers or suspicious lesions were noted. A new lesion with radiographic features compatible with HCC is defined as recurrence of HCC based on the reports of specialist in radiology. |
Countries
South Korea
Outcome results
None listed